Covid-19NETSINCOVIDNCT04412382
Covid-19: Possible Role of Neutrophil Extracellular Traps
An observational study of Covid-19, run by Azienda Ospedaliera Universitaria Integrata Verona at 1 site in Italy.
Trial summary
The process by which neutrophils expel DNA together with various proteins to the outside, forming a network structure called Neutrophil Extracellular Traps (NETs) constitutes a particular cell death that involves the destruction of the nuclear membrane before the plasmatic one. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Covid-19
- What is being tested?
- NETosis markers
- How many people
- 100 participants
- Where
- 1 siteItaly
- Study dates
- 1 Jun 2020to 31 Dec 2021
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Study population: Covid-19 patients aged ≥ 18 years admitted to the Covid sections of the Verona University Hospital. Control group: medical doctors and nurses worìking in the University Hospital of Verona.
Who may be able to join
None listed.
Who cannot join
- age <18 years;
- pregnancy;
- known autoimmune diseases.
- For the control group:
- positivity to Covid-19 swabs and / or the presence of IgM and IgG antibodies (sierological picture known from the samples taken by the Health surveillance System of the hospital).
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
Univeristy of Verona
Verona, 37136
chiara mozzini, MD PhD, +390458124262
About this study
The process by which neutrophils expel DNA together with various proteins to the outside, forming a network structure called Neutrophil Extracellular Traps (NETs) constitutes a particular cell death that involves the destruction of the nuclear membrane before the plasmatic one. This process is called NETosis and differs from other known forms of cell death, such as necrosis and apoptosis.
This process, however, if exaggerated, brings local or systemic damage. Viruses are known for their ability to evade the body's immune response. Only recently has it been seen that they can act as triggers for NETosis process.
Read more
In fact, many viruses can stimulate neutrophils to produce NETs. Virus-induced NETs can begin to circulate in an uncontrolled manner, leading to an extreme systemic response of the body with the production of immunocomplexes, cytokines, Interferon I etc.
To date, there are no data in the literature on the role of NETs in Covid-19 infection, a viral infection that leads to highly lethal interstitial pneumonia and for which there is currently no vaccine or specific therapy.
Advanced forms of Covid-19 are often characterized by hyperinflammation ("cytokine storm") with the development of an ARDS-like condition. Furthermore, reports of micro and macro thrombotic phenomena such as microangiopathy, pulmonary embolism (which has led to a careful evaluation procedure for antithrombotic prophylaxis and/or coagulation in Covid-19 patients) are increasingly frequent.
The primary objective of the study is to understand if NETs can be implicated in the response to Covid-19 and by which mechanisms. Concrete therapeutic proposals could derive from the knowledge and enhancement of this form of innate immunity.
To do this, it will be necessary to evaluate the activity of NETosis in Covid-19 patients and evaluate whether the clinical course of the disease (worsening vs healing) determines the degree of NETosis activity. Therefore, the association between mortality from Covid-19/survival and NETs activity will be studied.
Secondary objectives concern the possibility of studying the associations among NETosis markers and blood inflammation markers and among NETosis markers and the onset of peripheral or deep vein thrombosis.
Finally, the possibility that the plasma deriving from Covid-19 patients could trigger the NETosis process in vitro will be evaluated.
Read the detailed description
The process by which neutrophils expel DNA together with various proteins to the outside, forming a network structure called Neutrophil Extracellular Traps (NETs) constitutes a particular cell death that involves the destruction of the nuclear membrane before the plasmatic one. This process is called NETosis and differs from other known forms of cell death, such as necrosis and apoptosis.
Neutrophil death by NETs ejection (NETosis) was first described in 2004 by Brinkman.
NETs,as indicated by the word itself, represent a sort of network composed of DNA fibers, histones and proteins derived from the neutrophil granules, whose main function is to trap pathogens (mainly bacteria and fungi).This process is related to the innate immunity.
However, this process, if activated in an exaggerated way, implies itself local or systemic damage.
The DNA expelled during this process is a double stranded DNA, a dsDNA subtype. The dsDNA, which represents a fraction of the DNA available in the circulation (cell free DNA - cfDNA), originates from various processes of cell death, and is therefore correlated with the degree of tissue damage. It is present only in small quantities in healthy subjects.
It is important to underline how during the NETosis process the cellular redox state is altered, leading to an excess production of oxygen free radicals (Reactive Oxygen Species, ROS) and to the activation of the enzyme NADPH oxidase. The formation of NETs, and therefore the process of NETosis, were initially studied in the context of bacterial infections, but subsequently their role became increasingly clear in other conditions such as cancer, autoimmune diseases, lung diseases, atherosclerosis and venous thromboembolic disease.
In particular, NETosis seems to play an important role in all conditions characterized by venous and arterial thrombosis, as numerous evidences have confirmed.
NETosis has also been documented at the microvascular level, such as in vasculitis, thrombotic microangiopathies such as Moschowitz syndrome.
Viruses are known for their ability to evade the body's immune response. Recently it has been seen that they too can act as triggers of NETosis processes.
In fact, many viruses can stimulate neutrophils to produce NETs. Different responses of neutrophils have been seen, from classical NETosis, to the production of antiviral agents or even to the switch to apoptosis.
Virus-induced NETs (therefore complexes of dsDNA, histones, granular proteins) can begin to circulate in an uncontrolled way, leading to an extreme systemic response of the body with the production of immune complexes, cytokines, Interferon I etc.
NETosis appears to be closely linked to the inflammatory response. For example, it is known that in the neutrophilic granulocyte the PAD4 protein is present in the nucleus, it decondensates the chromatin and favors the formation of the NETs. On the other hand, NETs increase in patients with acute respiratory distress syndrome (ARDS) as observed in studies about bronchoalveolar lavage fluid, as well as in patients with acute respiratory failure during COPD exacerbation.
It is therefore clear that virus-induced NETosis acts as a double-edged sword: if on one hand there is the mechanical entrapment of the virus, on the other the inflammatory and immunological reaction triggered by the release of the NETs can be harmful itself.
To date, there are few data in the literature on the role of NETs in Covid-19 infection, a viral infection that can lead to highly lethal interstitial pneumonia and for which there is no vaccine or specific therapy today. Advanced forms of Covid-19 are often characterized by hyperinflammation ("cytokine storm") with the development of an ARDS-like condition. Furthermore, reports of micro and macro thrombotic phenomena such as microangiopathy, pulmonary embolism (which has led to a careful evaluation procedure for antithrombotic prophylaxis and / or coagulation in Covid-19 patients) are increasingly frequent.
OBJECTIVE OF THE STUDY The primary objective of the study is to understand if NETs can be implicated in the response to Covid-19 and by which mechanisms. Concrete therapeutic proposals could derive from the knowledge and enhancement of this form of innate immunity.
To do this, it will be necessary to evaluate the activity of NETosis in Covid-19 patients and evaluate whether the clinical course of the disease (worsening vs healing) determines the degree of NETosi activity. Therefore, the association between mortality from Covid-19/survival and NETs activity will be studied.
Secondary objectives concern the possibility of studying the various associations among NETosis markers and biohumoral indices of inflammation and among NETosi markers and the onset of peripheral or deep vein thrombosis.
Finally, the possibility that the plasma from Covid-19 patients could trigger the NETosis process in vitro will be evaluated.
PLANNED PROCEDURES and COLLECTED INFORMATION Medical examination: (blood pressure, heart rate and SpO2, which will allow to evaluate the precise PaO2 / FiO2 ratio).
As in normal clinical practice, Covid-19 patients will undergo venous sampling for the determination of blood count, creatinine, lipid profile, PCR, D-dimer, LDH, liver function indices and blood glucose.
Precise medical history will be drawn up for each subject. Patients will undergo:electrocardiogram and chest x-ray and, in selected cases, chest CT scan, depending on their clinical need.
They will also undergo venous echo-color Doppler lower limbs examination. A complete analysis of the venous axes will not be necessary. NETosis markers (Cf-DNA. MPO-DNA, Cit-H3) and the cytokines IL-6 and IL-1β will be analyzed from the subjects' plasma.
Spittle sample (or bronchoalveolar fluid if necessary for diagnostic-therapeutic purposes) will be collected and the detection of NETs at electron microscopy will be assessed.
Informed consent will be requested.
CALCULATION OF THE SAMPLE The sample size was defined on the basis of the number of admissions for Covid-19 in the months of March-April 2020 and on the decrease in numbers in the current period.
100 subjects (50 patients and 50 controls) are expected to be enrolled.
STATISTICAL ANALYSIS Hypothetical statistical analysis: the data will be collected through descriptive statistics. The estimates will be accompanied by appropriate 95% confidence intervals. The level of statistical significance is set at 5%. The statistical program Stata 14.2 will be used. Planned test: t-test and Mann-Whitney test. Correlations will be evaluated through Pearson or Spearman coefficients. Furthermore, Kaplan-Meier analyzes will be carried out with the use of Log-Rank test and Cox regression for survival analysis.
- Conditions
- Covid-19
- Being tested
- NETosis markers
- Keywords
- Covid-19, neutrophil extracellular traps
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NETosis markersDiagnostic test
NETosis markers (Cf-DNA. MPO-DNA, Cit-H3) and the cytokines IL-6 and IL-1β will be analyzed from the subjects' plasma.
Spittle sample (or bronchoalveolar fluid if necessary for diagnostic-therapeutic purposes) will be collected and the detection of NETs at electron microscopy will be assessed.
| Study group | Role | What they receive |
|---|---|---|
| covid-19 | Study population: Covid-19 patients aged ≥ 18 years admitted to the Covid sections of the Verona University Hospital. Based on the ongoing epidemic emergency and the lack of specific therapy, we believe that to date this should be the only INCLUSION CRITERION. Receives: Diagnostic Test: NETosis markers | |
| control | Control group: medical doctors and nurses working in the University Hospital of Verona without known autoimmune diseases nor cancer. Receives: Diagnostic Test: NETosis markers |
What is being measured
The primary outcome is the main question the study is designed to answer.
NETOSIS AND MORTALITY
correlation among plasma levels of NETosis markers and Covid-19 mortality
Measured: 1 year
NETOSIS AND DCOVID-19 SEVERITY
correlation among plasma levels of NETosis markers and disease severity (that is duration of hospitalization in days and any need for passage to intensive care with non-invasive ventilation or intubation);
Measured: 1 year
Secondary outcomes (2)
NETOSIS AND INFLAMMATION
correlation among plasma levels of NETosis markers and clinical inflammation biomarkers (white blood cells, PCR IL-6-IL-1β)
Measured: 1 year
NETOSIS AND VENOUS THROMBOSIS
correlation among plasma levels of NETosis markers and the onset of deep vein thrombosis and / or the increase in D-dimer values.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jun 2020
- Study start1 Jun 2020
- Primary completion31 Dec 2020 (estimated)
- Study completion31 Dec 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Covid-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chiara Mozzini, Azienda Ospedaliera Universitaria Integrata Verona
- Investigators
- DOMENICO GIRELLI, MD-PhD, Study chair, Universita di Verona
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04412382
- Sponsor's protocol ID
- NETS IN COVID-19
- Acronym
- NETSINCOVID
- Status last verified
- Jul 2020
- First submitted
- 26 May 2020
- Last updated
- 8 Jul 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: study protocol and results
Publications
Mozzini C, Girelli D. The role of Neutrophil Extracellular Traps in Covid-19: Only an hypothesis or a potential new field of research? Thromb Res. 2020 Jul;191:26-27. doi: 10.1016/j.thromres.2020.04.031. Epub 2020 Apr 27. No abstract available.
PubMed 32360977
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Covid-19: Possible Role of Neutrophil Extracellular Traps
- ClinicalTrials.gov ID
- NCT04412382
- Acronym / sponsor ID
- NETSINCOVID / NETS IN COVID-19
- Conditions
- Covid-19
- Keywords
- Covid-19, neutrophil extracellular traps
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Azienda Ospedaliera Universitaria Integrata VeronaUniversity, hospital or other
- Study start
- 1 Jun 2020 (actual)
- Primary completion
- 31 Dec 2020 (estimated)
- Study completion
- 31 Dec 2021 (estimated)
- First posted
- 2 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The process by which neutrophils expel DNA together with various proteins to the outside, forming a network structure called Neutrophil Extracellular Traps (NETs) constitutes a particular cell death that involves the destruction of the nuclear membrane before the plasmatic one. This process is called NETosis and differs from other known forms of cell death, such as necrosis and apoptosis.
This process, however, if exaggerated, brings local or systemic damage. Viruses are known for their ability to evade the body's immune response. Only recently has it been seen that they can act as triggers for NETosis process.
In fact, many viruses can stimulate neutrophils to produce NETs. Virus-induced NETs can begin to circulate in an uncontrolled manner, leading to an extreme systemic response of the body with the production of immunocomplexes, cytokines, Interferon I etc.
To date, there are no data in the literature on the role of NETs in Covid-19 infection, a viral infection that leads to highly lethal interstitial pneumonia and for which there is currently no vaccine or specific therapy.
Advanced forms of Covid-19 are often characterized by hyperinflammation ("cytokine storm") with the development of an ARDS-like condition. Furthermore, reports of micro and macro thrombotic phenomena such as microangiopathy, pulmonary embolism (which has led to a careful evaluation procedure for antithrombotic prophylaxis and/or coagulation in Covid-19 patients) are increasingly frequent.
The primary objective of the study is to understand if NETs can be implicated in the response to Covid-19 and by which mechanisms. Concrete therapeutic proposals could derive from the knowledge and enhancement of this form of innate immunity.
To do this, it will be necessary to evaluate the activity of NETosis in Covid-19 patients and evaluate whether the clinical course of the disease (worsening vs healing) determines the degree of NETosis activity. Therefore, the association between mortality from Covid-19/survival and NETs activity will be studied.
Secondary objectives concern the possibility of studying the associations among NETosis markers and blood inflammation markers and among NETosis markers and the onset of peripheral or deep vein thrombosis.
Finally, the possibility that the plasma deriving from Covid-19 patients could trigger the NETosis process in vitro will be evaluated.
Detailed description
The process by which neutrophils expel DNA together with various proteins to the outside, forming a network structure called Neutrophil Extracellular Traps (NETs) constitutes a particular cell death that involves the destruction of the nuclear membrane before the plasmatic one. This process is called NETosis and differs from other known forms of cell death, such as necrosis and apoptosis.
Neutrophil death by NETs ejection (NETosis) was first described in 2004 by Brinkman.
NETs,as indicated by the word itself, represent a sort of network composed of DNA fibers, histones and proteins derived from the neutrophil granules, whose main function is to trap pathogens (mainly bacteria and fungi).This process is related to the innate immunity.
However, this process, if activated in an exaggerated way, implies itself local or systemic damage.
The DNA expelled during this process is a double stranded DNA, a dsDNA subtype. The dsDNA, which represents a fraction of the DNA available in the circulation (cell free DNA - cfDNA), originates from various processes of cell death, and is therefore correlated with the degree of tissue damage. It is present only in small quantities in healthy subjects.
It is important to underline how during the NETosis process the cellular redox state is altered, leading to an excess production of oxygen free radicals (Reactive Oxygen Species, ROS) and to the activation of the enzyme NADPH oxidase. The formation of NETs, and therefore the process of NETosis, were initially studied in the context of bacterial infections, but subsequently their role became increasingly clear in other conditions such as cancer, autoimmune diseases, lung diseases, atherosclerosis and venous thromboembolic disease.
In particular, NETosis seems to play an important role in all conditions characterized by venous and arterial thrombosis, as numerous evidences have confirmed.
NETosis has also been documented at the microvascular level, such as in vasculitis, thrombotic microangiopathies such as Moschowitz syndrome.
Viruses are known for their ability to evade the body's immune response. Recently it has been seen that they too can act as triggers of NETosis processes.
In fact, many viruses can stimulate neutrophils to produce NETs. Different responses of neutrophils have been seen, from classical NETosis, to the production of antiviral agents or even to the switch to apoptosis.
Virus-induced NETs (therefore complexes of dsDNA, histones, granular proteins) can begin to circulate in an uncontrolled way, leading to an extreme systemic response of the body with the production of immune complexes, cytokines, Interferon I etc.
NETosis appears to be closely linked to the inflammatory response. For example, it is known that in the neutrophilic granulocyte the PAD4 protein is present in the nucleus, it decondensates the chromatin and favors the formation of the NETs. On the other hand, NETs increase in patients with acute respiratory distress syndrome (ARDS) as observed in studies about bronchoalveolar lavage fluid, as well as in patients with acute respiratory failure during COPD exacerbation.
It is therefore clear that virus-induced NETosis acts as a double-edged sword: if on one hand there is the mechanical entrapment of the virus, on the other the inflammatory and immunological reaction triggered by the release of the NETs can be harmful itself.
To date, there are few data in the literature on the role of NETs in Covid-19 infection, a viral infection that can lead to highly lethal interstitial pneumonia and for which there is no vaccine or specific therapy today. Advanced forms of Covid-19 are often characterized by hyperinflammation ("cytokine storm") with the development of an ARDS-like condition. Furthermore, reports of micro and macro thrombotic phenomena such as microangiopathy, pulmonary embolism (which has led to a careful evaluation procedure for antithrombotic prophylaxis and / or coagulation in Covid-19 patients) are increasingly frequent.
OBJECTIVE OF THE STUDY The primary objective of the study is to understand if NETs can be implicated in the response to Covid-19 and by which mechanisms. Concrete therapeutic proposals could derive from the knowledge and enhancement of this form of innate immunity.
To do this, it will be necessary to evaluate the activity of NETosis in Covid-19 patients and evaluate whether the clinical course of the disease (worsening vs healing) determines the degree of NETosi activity. Therefore, the association between mortality from Covid-19/survival and NETs activity will be studied.
Secondary objectives concern the possibility of studying the various associations among NETosis markers and biohumoral indices of inflammation and among NETosi markers and the onset of peripheral or deep vein thrombosis.
Finally, the possibility that the plasma from Covid-19 patients could trigger the NETosis process in vitro will be evaluated.
PLANNED PROCEDURES and COLLECTED INFORMATION Medical examination: (blood pressure, heart rate and SpO2, which will allow to evaluate the precise PaO2 / FiO2 ratio).
As in normal clinical practice, Covid-19 patients will undergo venous sampling for the determination of blood count, creatinine, lipid profile, PCR, D-dimer, LDH, liver function indices and blood glucose.
Precise medical history will be drawn up for each subject. Patients will undergo:electrocardiogram and chest x-ray and, in selected cases, chest CT scan, depending on their clinical need.
They will also undergo venous echo-color Doppler lower limbs examination. A complete analysis of the venous axes will not be necessary. NETosis markers (Cf-DNA. MPO-DNA, Cit-H3) and the cytokines IL-6 and IL-1β will be analyzed from the subjects' plasma.
Spittle sample (or bronchoalveolar fluid if necessary for diagnostic-therapeutic purposes) will be collected and the detection of NETs at electron microscopy will be assessed.
Informed consent will be requested.
CALCULATION OF THE SAMPLE The sample size was defined on the basis of the number of admissions for Covid-19 in the months of March-April 2020 and on the decrease in numbers in the current period.
100 subjects (50 patients and 50 controls) are expected to be enrolled.
STATISTICAL ANALYSIS Hypothetical statistical analysis: the data will be collected through descriptive statistics. The estimates will be accompanied by appropriate 95% confidence intervals. The level of statistical significance is set at 5%. The statistical program Stata 14.2 will be used. Planned test: t-test and Mann-Whitney test. Correlations will be evaluated through Pearson or Spearman coefficients. Furthermore, Kaplan-Meier analyzes will be carried out with the use of Log-Rank test and Cox regression for survival analysis.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 1 Year
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| covid-19 | – | Diagnostic Test: NETosis markersStudy population: Covid-19 patients aged ≥ 18 years admitted to the Covid sections of the Verona University Hospital. Based on the ongoing epidemic emergency and the lack of specific therapy, we believe that to date this should be the only INCLUSION CRITERION. |
| control | – | Diagnostic Test: NETosis markersControl group: medical doctors and nurses working in the University Hospital of Verona without known autoimmune diseases nor cancer. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Study population: Covid-19 patients aged ≥ 18 years admitted to the Covid sections of the Verona University Hospital. Control group: medical doctors and nurses worìking in the University Hospital of Verona.
Key inclusion criteria (0 listed)
Key exclusion criteria (5 listed)
- age <18 years;
- pregnancy;
- known autoimmune diseases.
- positivity to Covid-19 swabs and / or the presence of IgM and IgG antibodies (sierological picture known from the samples taken by the Health surveillance System of the hospital).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NETosis markersNETosis markers (Cf-DNA. MPO-DNA, Cit-H3) and the cytokines IL-6 and IL-1β will be analyzed from the subjects' plasma. Spittle sample (or bronchoalveolar fluid if necessary for diagnostic-therapeutic purposes) will be collected and the detection of NETs at electron microscopy will be assessed. | Diagnostic test | control, covid-19 |
Primary outcome
NETOSIS AND MORTALITY
Time frame: 1 year
correlation among plasma levels of NETosis markers and Covid-19 mortality
NETOSIS AND DCOVID-19 SEVERITY
Time frame: 1 year
correlation among plasma levels of NETosis markers and disease severity (that is duration of hospitalization in days and any need for passage to intensive care with non-invasive ventilation or intubation);
2 secondary outcomes
NETOSIS AND INFLAMMATION
Time frame: 1 year
NETOSIS AND VENOUS THROMBOSIS
Time frame: 1 year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2020.
- Background: PubMed 32360977Mozzini C, Girelli D. The role of Neutrophil Extracellular Traps in Covid-19: Only an hypothesis or a potential new field of research? Thromb Res. 2020 Jul;191:26-27. doi: 10.1016/j.thromres.2020.04.031. Epub 2020 Apr 27. No abstract available.
- Individual participant dataSharing planned: Yes. study protocol and results
Related trials for Covid-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
DOMENICO GIRELLI, MD-PhD study chair
Universita di Verona
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid-19, run by Azienda Ospedaliera Universitaria Integrata Verona at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact CHIARA MOZZINI, MD-PhD (+39 0458124262, chiara.mozzini@univr.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
NETOSIS AND MORTALITY (time frame: 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04412382, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2020.